الفهرس 
CHRONIC MYELOID LEUKEMIA (CML)Only 14 pages are availabe for public view
 |  | from | 158 |  |  |
| | | from | 158 | | |
Abstract
Background: chronic myeloid leukemia (CML) is a malignant hematologic disease that arises from the pluripotent hematopoietic stem cells. According to the guidelines issued by the European LeukemiaNet (ELN), BCR-ABL transcript levels on the international scale (BCR-ABLIS) at 3 and 6 months are defined as indicators of the early efficacy of first-line TKI treatment. A BCR-ABLIS ≤10% after 3 months of TKI treatment or BCR-ABLIS <1% after 6 months of treatment indicates an optimal response to TKI therapy with no need to adjust the therapeutic strategy.
Objectives: The present study aimed to investigate the impact of early molecular response (EMR; BCR-ABL ≤ 10% on the International scale [BCR-ABLIS] at 3 or 6 months) on outcomes in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with Nilotinib.
Patients and Methods: The present study was enrolled from 2018 to 2020 at Nasser Institute for Research and Treatment and the National Cancer Institute. This is a prospective cohort study done on (94) newly diagnosed cases of CML in chronic Phase.
Results: Results of the current study showed that (74.5%) of the studied cases were male. Baseline serum creatinine (Scr) was ≥1.4 mg/dL in (62.8%) of the studied cases. eosinophilia was present in only (12.8%). In the present study, Baseline uric acid (UA) was <6 mg/dL in (62.8%) of the studied cases. Baseline peripheral blasts were <5% in (86.2%) of the studied cases. Splenomegaly was present in only (3.2%) of the studied cases. Age at diagnosis was <55 in (87.2%) of the studied cases. The present study results showed that, in cases not achieved EMR; the majority (75%) had Scr <1.4 mg/dL, while in cases achieved EMR (64.4%) had Scr ≥1.4 mg/dL. There was none statistically significant difference between the two groups regarding baseline Scr.
Conclusion: Early molecular response (EMR) is an important prognostic significance for CML patients treated with Nilotinib. Patients who achieved EMR had significantly better outcomes. Achieving MR3.0 should be a priority in CML-CP patients who have a 3-month BCR-ABL ≤ 10% and 6-month BCR-ABL ≤ 10%.